首页> 外文期刊>Endocrine practice: official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists >LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY
【24h】

LIPID ACCUMULATION PRODUCT, VISCERAL ADIPOSITY INDEX, AND CHINESE VISCERAL ADIPOSITY INDEX AS MARKERS OF CARDIOMETABOLIC RISK IN ADULT GROWTH HORMONE DEFICIENCY PATIENTS: A CROSS-SECTIONAL STUDY

机译:脂质累积产品,内脏肥胖指数和中国内脏肥胖指数作为成人生长激素缺乏症患者心细素风险的标志:横截面研究

获取原文
获取原文并翻译 | 示例
           

摘要

Objective: Adult growth hormone deficiency (AGHD) is associated with cardiometabolic risk factors. Given that cardiovascular disease (CVD) is an important cause of morbidity and mortality in the AGHD population, there is a need for alternative, noninvasive methods of assessing cardiometabolic risk in this population. The Chinese visceral adiposity index (CVAI) is a new marker of visceral fat dysfunction based on age, body mass index (BMI), waist circumference (WC), and metabolic parameters. CVAI is well correlated with insulin resistance (IR) and is better at predicting metabolic syndrome (MS) than BMI and WC. This study aims to examine the reliability of the lipid accumulation product (LAP), visceral adiposity index (VAI), and CVAI as cardiometabolic risk markers in AGHD patients.
机译:目的:成人生长激素缺乏(AGHD)与心脏差异危险因素有关。 鉴于心血管疾病(CVD)是AGHD人口中发病率和死亡率的重要原因,需要替代,非侵入性的方法来评估该人群中的心脏代谢风险。 中国内脏肥胖指数(CVAI)是基于年龄,体重指数(BMI),腰围(WC)和代谢参数的内心脂肪功能障碍的新标志物。 CVAI与胰岛素抵抗(IR)良好相关,并且更好地预测代谢综合征(MS)而不是BMI和WC。 本研究旨在研究脂肪累积产品(LAP),内脏肥胖指数(VAI)和CVAI作为AGD患者的心肌差异风险标志物的可靠性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号